𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Genetic evidence for the involvement of τ in progressive supranuclear palsy

✍ Scribed by Chris Conrad; Athena Andreadis; John Q. Trojanowski; Dennis W. Dickson; David Kang; Xiaohua Chen; Wigbert Wiederholt; Larry Hansen; Dr Eliezer Masliah; Leon J. Thal; Robert Katzman; Yu Xia; Tsunao Saitoh

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
538 KB
Volume
41
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Diagnostic accuracy of progressive supra
Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank
✍ Keith A. Josephs; Dennis W. Dickson 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

## Abstract Diagnostic accuracy has been addressed previously for Parkinson's disease in a brain bank collection, but accuracy of progressive supranuclear palsy (PSP) has not been addressed in a similar setting. Clinical and genetic features of pathologically confirmed cases of PSP were compared wi

Mitochondrial impairment in the cerebell
Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy
✍ Larry C.H. Park; David S. Albers; Hui Xu; J. Gordon Lindsay; M. Flint Beal; Gary 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

## Abstract Abnormalities in energy metabolism and oxidative stress accompany many neurodegenerative diseases, including progressive supranuclear palsy (PSP). Previously, we showed decreased activities of a mitochondrial enzyme complex, α‐ketoglutarate dehydrogenase complex (KGDHC), and marked incr

Efaroxan, an alpha-2 antagonist, in the
Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy
✍ Prof. Olivier Rascol; Kasia Sieradzan; Hélène Peyro-Saint-Paul; Claire Thalamas; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB

## Abstract We have tested, in a prospective randomized, double‐blind, placebo‐controlled, crossover, 12‐week study, the effects of 2 mg efaroxan, a potent alpha‐2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant chang

Increased tau burden in the cortices of
Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome
✍ Yoshio Tsuboi; Keith A. Josephs; Bradley F. Boeve; Irene Litvan; Richard J. Case 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

## Abstract The objective of this study is to better define the pathological characteristics of pathologically proven progressive supranuclear palsy (PSP) presenting with the corticobasal syndrome (CBS). PSP is characterized by early falls, vertical supranuclear ophthalmoplegia, and axial rigidity,

Relationship of the extended tau haploty
Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy
✍ Wan-Kyng Liu; Tien V. Le; Jennifer Adamson; Matthew Baker; Natalie Cookson; John 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 880 KB

Two extended haplotypes of the tau gene (H1 and H2) have been described. The frequency of H1 haplotype is increased in progressive supranuclear palsy (PSP). PSP is associated with filamentous tau lesions in neurons and glia, which are reportedly composed exclusively of tau isoforms with four repeats